Gulsevim Aydin,Matthew Ball,Thomas George Bishop,Matthew Burns,Andrew D. Campbell,Robert J. Cox,Kuangchu Dai,David Dave,Heidi Fisk,Laura S. Hamilton,Claire Heffernan,Jean-Marc Henry,Stephen W. Holman,Martin F. Jones,Gary M. Noonan,Bharti Patel,David Streather,Simone Tomasi
Process development activities required to develop a robust and scalable synthetic route to AZD7594 (1) are disclosed. Included in this paper is the rationale for the selection of a palladium-mediated Buchwald–Hartwig coupling to form a key C–N bond. Reaction optimization and understanding were performed to minimize impurity formation and to develop a robust control strategy. The optimized synthetic sequence was used to manufacture 220 kg of AZD7594 (1) for clinical trials.